Cefepime
FDA issued an early communication about new safety information and the request for additional data concerning the risk of death in patients treated with cefepime. The May 2007 issue of The Lancet Infectious Diseases (Efficacy and safety of cefepime: a systematic review and meta-analysis) reported the increased mortality with the use of cefepime, a broad spectrum B-lactam antibiotic currently approved for the treatment of a variety of infections due to susceptible strains of microorganisms. The article describes a higher all-cause mortality in patients treated with cefepime compared to other B-lactam antibiotics. If someone has been prescribed this drug, I recommend that they contact their treating physician to discuss this breaking news.
Read the complete MedWatch 2007 Safety Summary including a link to the Early Communication Sheet regarding this ongoing safety review at:
http://www.fda.gov/medwatch/safety/2007/safety07.htm#Cefepime
http://www.bailey-law.com/lawyer-attorney-1215852.html